SOHM Inc. develops pharmaceutical and biotechnology businesses around generic drugs, gene-editing tools, health and wellness products, and related commercialization capabilities. Company news centers on ABBIE, its proprietary genome-engineering platform for programmable DNA insertion, including preclinical work, non-viral integration concepts, patent allowances, technical publications, and engineered cell models such as SKOV3-GYS1 for drug-discovery applications.
Updates also cover SOHM's operating footprint, product and service communications, licensing and partnership themes, and governance changes. Additional announcements reference pharmaceuticals, nutraceuticals, topicals, and biotechnology-driven product categories as the company expands its commercial and research focus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.